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Cord blood transplantation (CBT) is a known risk factor for human herpesvirus-6 (HHV-6) infection. We
analyzed the nature of HHV-6 infections in 125 double-unit CBT recipients (median age, 42 years) trans-
planted for hematologic malignancies with calcineurin inhibitor/mycophenolate mofetil prophylaxis and no
antithymocyte globulin. One hundred seventeen patients (94%) reactivated HHV-6 by quantitative plasma
PCR (median peak, 7600 copies/mL; range, 100 to 160,000) at a median of 20 days (range, 10 to 59) after
transplantation. HHV-6 encephalitis occurred in 2 patients (1.6%), of whom 1 died and 1 recovered with
therapy. No association was found between high-level HHV-6 viremia (10,000 or 25,000 copies/mL) and
age, diagnosis, conditioning intensity, or dominant unit characteristics or between high-level viremia and
transplant outcomes (engraftment, cytomegalovirus reactivation, day 100 grades II to IV acute graft-versus-
host disease, day 100 transplant-related mortality, or 1-year disease-free survival). HHV-6 therapy delayed
the onset of cytomegalovirus reactivation. Interestingly, HHV-6 resolution was observed in untreated pa-
tients, and resolution of viremia correlated with absolute lymphocyte count recovery. We observed a low
incidence of encephalitis and no association with CBT outcomes. Our data suggest therapy in uncomplicated
viremia may not be warranted. However, further investigation of the risk-to-beneﬁt of HHV-6 viremia
treatment and standardization of PCR testing is required.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION transplantation (HSCT) recipients [4,5], and end-organ dis-
Human herpesvirus-6 (HHV-6) is a member of the Rose-
olovirus genus in the Betaherpesvirinae subfamily of human
herpesviruses. Type A and B variants have been identiﬁed,
exhibiting different biologic characteristics and disease as-
sociations. HHV-6B is highly prevalent in the human popu-
lation, affecting over 90% of healthy individuals during
childhood [1]. Primary HHV-6 infection is recognized as the
cause of exanthema subitum and fever [2]. Like other her-
pesviruses, HHV-6 remains latent in host cells, and very few
cases of recurrent infection ever occur in immunocompetent
adults [3]. Early HHV-6 reactivation, however, occurs
in about half of allogeneic hematopoietic stem celledgments on page 792.
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14.02.010ease is an important complication after allogeneic HSCT [6-
8]. HHV-6 reactivation can cause life-threatening hepatitis
[9], interstitial pneumonia [10], and encephalitis [7,11-15].
Reactivation has also been associated with subtle cognitive
dysfunction [16], fever, skin rash [5,6], and delayed neutro-
phil and platelet engraftment [1]. HHV-6 can infect he-
matopoietic progenitor cells, and resultant reduction in
colony formation in vitro has been described [17]. This could
explain the delayed engraftment reported in patients who
reactivate HHV-6 after allografting [18,19]. HHV-6 may also
have immunomodulating properties that could enhance the
reactivation of cytomegalovirus (CMV) [11].
Reported risk factors for HHV-6 reactivation in HSCT
recipients include myeloablative conditioning [20,21],
1-antigen HLA mismatch [11,22], CMV reactivation [5,11,23],
total body irradiation [24], unrelated donor grafts [25], bone
marrow grafts [26], gender-mismatched grafts [8], and theTransplantation.
Table 1
Demographics of 125 Patients and Their Grafts
Characteristic Value
Median age, yr 42 (range, .9-69)
Median weight, kg 67 (range, 8-125)
Diagnosis, n (%)
AML 43 (34)
ALL 24 (19)
Other leukemia, MDS, CML 12 (10)
Lymphoma, CLL 46 (37)
Conditioning, n (%)
Myeloablative 94 (75)
Nonmyeloablative 31 (25)
Median unit-to-recipient HLA match
10 allele 6/10 (range, 2-9/10)
Median infused TNC count  107/kg
Larger unit 2.7 (range, 1.4-11.3)
Smaller unit 2.0 (range, .9-7.1)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leu-
kemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leu-
kemia; CLL, chronic lymphocytic leukemia; TNC, total nucleated cell.
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recently published study of 235 patients who underwent
allogeneic HSCT with matched related sibling or unrelated
donors including 34 recipients of CB, HHV-6 reactivation
reduced day 180 overall survival [29]. Studies in children
have correlated blood levels > 1000 viral copies/mL with
increased nonrelapse mortality [30]. Studies in CB trans-
plantation (CBT) recipients, in particular, indicate an
increased incidence and severity of HHV-6eassociated dis-
ease [13,15]. The goal of the current study was to analyze the
incidence and severity of HHV-6 viremia and end-organ
disease and the natural history of HHV-6 viremia in the
ﬁrst 100 days after CBT in patients transplanted at Memorial-
Sloan Kettering Cancer Center (MSKCC).
METHODS
Patient and Graft Characteristics
Eligible patients for this retrospective analysis included all consecutive
adult and pediatric ﬁrst allograft recipients transplanted with CB for the
treatment of hematologic malignancies at MSKCC. All CBT recipients during
the study period received double-unit grafts. Of 141 consecutive double-unit
CBT recipients transplanted from February 28, 2006 throughMarch 21, 2012,
125 were assessable for HHV-6 reactivation. Sixteen patients were not, 14
due to insufﬁcient testing (1 or fewer tests performed due to physician
preference but not due to early death) and 2 due to death within the ﬁrst
3 weeks after CBT unrelated to HHV-6. All patients provided written
informed consent for transplantation and outcome analysis, and the study
was approved by the MSKCC Institutional Review/Privacy Board.
CB units were selected on the basis of 4-6/6 HLA-A, -B antigen, and
-DRB1 allele match to the recipient, a cryopreserved total nucleated cell
count of at least 1.5  107/kg/unit (increased to 2.0  107/kg/unit in 2011),
and the bank of origin as previously described [31]. Unit-to-unit HLA match
was not considered in CB unit selection.
Conditioning Regimens and Graft-versus-Host Disease Prophylaxis
All patients were hospitalized in high-efﬁciency particulate aireﬁltered
rooms and received similar supportive care. Pretransplant conditioning
varied according to patient age, diagnosis, remission status, extent of prior
therapy, and comorbidities and consisted of high-dose myeloablative,
reduced-intensity, or nonmyeloablative regimens. All patients received
granulocyte colony-stimulating factor after CBT until neutrophil recovery.
All patients received a calcineurin inhibitor and mycophenolate mofetil for
graft-versus-host disease (GVHD) prophylaxis starting day e3, and none
received antithymocyte globulin [32,33].
Viral Prophylaxis, Monitoring, and Antiviral Treatment
All patients received acyclovir antiviral prophylaxis at 250 mg/m2 i.v.
every 8 hours followed by 400 mg orally twice daily upon discharge (or
200 mg every 8 hours in children). CMV-seropositive recipients did not
receive CMV-speciﬁc prophylaxis. Post-transplant surveillance for HHV-6
was performed at Viracor-IBT Laboratories (Lee’s Summit, MO) using
quantitative PCR of HHV-6 DNA from plasma. The lower limit of detection
was 100 DNA copies/mL [34]. Patients were monitored post-transplant with
testing once to twice weekly from day 14 (or earlier if clinically indicated) to
approximately day 60 and thereafter at the treating physicians discretion.
Over the course of the study, CMV reactivation was monitored by anti-
genemia until June 2010 after which PCR was substituted. Patients treated
for HHV-6 received i.v. foscarnet at either induction (90 mg/kg i.v. every
12 hours) or maintenance (90 mg/kg i.v. every 24 hours) doses. Induction
versus maintenance dosing was chosen per physician preference according
to the patient’s renal function. Therapy guidelines were not standardized
during the study period, however, and institution of therapy depended on
the patient’s clinical status (including symptoms such as fever and renal
function), the viremia level, and the treating physician’s preference.
Study Deﬁnitions
HHV-6 reactivationwas deﬁned as1 positive HHV-6 PCR value of100
copies/mL. The duration of HHV-6 viremia was measured as days from the
ﬁrst to last positive test. A single positive test was, therefore, recorded as
1 day of viremia. HHV-6 encephalitis was deﬁned as clinical encephalitis
(confusion, memory loss, and seizures) combined with magnetic resonance
imaging ﬁndings consistent with limbic encephalitis in the setting of
simultaneous HHV-6 viremia [35]. Isolation of HHV-6 from cerebrospinal
ﬂuid was not mandatory for the diagnosis of encephalitis. HHV-6 pneu-
monia was deﬁned as pulmonary symptoms with inﬁltrates and concurrentHHV-6 isolation from bronchoalveolar lavage (BAL) in the absence of other
causative organisms, as previously described [36].
Statistical Analysis
Fisher exact test compared categorical variables andWilcoxon rank sum
test compared continuous variables in patients with high and low peak
HHV-6 viremia levels. Kaplan-Meier methodology estimated 1-year disease-
free survival (DFS). The cumulative incidence of neutrophil and platelet
engraftment was evaluated using competing risk analysis with death as the
competing event. The incidence of acute GVHD was estimated, treating
death and relapse as competing events. For the incidence of relapse,
transplant-related mortality (TRM) was the competing event, and for the
TRM calculation, relapse was the competing event. Time-dependent Cox
regression assessed the association between high HHV-6 viremia and CBT
outcomes. For DFS, the hazard ratio and 95% conﬁdence interval (CI) was
estimated, and cause-speciﬁc hazard ratios were estimated for other
transplant outcomes.
Time-dependent Cox regression was used to analyze the incidence of
CMV reactivation in relation to high- versus low-level HHV-6 viremia. The
association between weekly median values of HHV-6 and absolute
lymphocyte counts was evaluated using Spearman’s correlation coefﬁcient
and tested considering repeated measures over time using generalized
estimating equation method with an unstructured correlation structure and
robust covariance matrix. The Wilcoxon rank sum test was used to compare
HHV-6 viral loads in patients who were observed and those who were
treated. A day 45 landmark analysis of 1-year DFS was performed to
examine the effect of treatment in patients who had HHV-6 viremia. In all
analyses statistical signiﬁcance was deﬁned as P < .05 based on a 2-sided
test. Statistical analyses were performed using SAS 9.2 (SAS Institute Inc.,
Cary, NC) and R version 2.13 (The R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Characteristics of Patients and Grafts
Table 1 provides the patient and graft demographics for
the entire cohort (N¼ 125). Median patient agewas 42 years,
and most patients had acute leukemia and received mye-
loablative conditioning.
Incidence, Severity and Duration of HHV-6 Viremia
Figure 1 depicts the incidence and severity of HHV-6
viremia in the ﬁrst 100 days post-CBT. One hundred seven-
teen of 125 patients (94%) reactivated HHV-6. The median
day of HHV-6 onset was 20 days post-CBT (range, 10 to
59 days), the median peak was 7600 copies/mL (range,100 to
160,000), and the median time to peak viremia was 23 days
(range, 12 to 62 days). The median duration of viremia was
10 days (range, 1 to 60 days).
Patients were classiﬁed as having low-level (peak
viral load < 10,000 copies/mL) or high-level (peak viral
Figure 1. The incidence and severity of HHV-6 viremia in the ﬁrst 100 days
after CBT (N ¼ 125) Nearly all patients reactivated, 77%  1000, but only 6%
> 100,000 and none  1,000,000.
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100 days. This cut-off was arbitrary based on the distribution
of viral load in our patient population and previous reports of
this level representing a clinically relevant threshold of viral
load for increased HHV-6 end-organ disease risk [37]. Of
patients with high-level viremia  10,000 copies/mL, 33 of
51 (65%) had fever at viremia onset. This comparedwith 22 of
66 patients (33%) with low-level viremia (P < .01).HHV-6 End-Organ Disease
Two patients developed HHV-6 encephalitis. The ﬁrst was
a heavily pretreated 62-year-old with lymphoma who un-
derwent nonmyeloablative CBT. The patient reactivated
HHV-6 on day 23 to 13,100 copies/mL. Foscarnet was started
on day 27 and continued for 15 days with resolution of
viremia. On day 43 the patient developed confusion, mag-
netic resonance imaging showed encephalitis, and cerebro-
spinal was positive for HHV-6. Foscarnet was resumed, but
the patient died of HHV-6 encephalitis. The second patient
was a 16-year-old myeloablative CBT recipient with acute
lymphoblastic leukemia who reactivated HHV-6 on day 18 to
21,000 copies/mL. On day 21, HHV-6 was 118,000 copies/mL.Table 2
Comparison of Recipient and Graft Demographics in 125 Patients with No or Low-
Characteristics No or Low-Level V
(<10,000 copies/m
Median age, yr 42 (range, 1-69)
Median weight, kg 70 (range, 8-104)
Diagnosis, n (%)
Acute leukemia, MDS, CML (n ¼ 79) 41 (52)
Lymphoma including CLL (n ¼ 46) 33 (72)
Conditioning, n (%)
TBI-based myeloablative (n ¼ 78) 44 (56)
Chemotherapy-based myeloablative (n ¼ 16) 8 (50)
Nonmyeloablative (n ¼ 31) 22 (71)
Median unit-to-recipient HLA match*
A, -B antigen, -DRB1 allele 5/6 (range, 4-6/6)
10 allele 6/10 (range, 2-9/1
Median dose
Infused TNC count  107/kg* 2.0 (range, 1.2-11
Infused CD34þ  105/kg* 1.0 (range, .1-4.8)
MDS indicates myelodysplastic syndrome; CML, chronic myelogenous leukemia;
nucleated cell.
* Unit dominant in engraftment.On day 24 the patient developed delirium, and magnetic
resonance imaging showed encephalitis. The patient was
treated with foscarnet induction and made a full recovery.
Four additional patients had HHV-6 isolated from BAL in
the setting of viremia. At the time of BAL, HHV-6 was not
detected in the blood in 1 patient already on foscarnet
therapy, and blood PCRwas 9000, 22,400, and 65,500 copies/
mL, respectively, in the other 3 patients. None of these pa-
tients fulﬁlled criteria for HHV-6 pneumonia, although 2 of
the 4 patients received foscarnet therapy for viremia.Recipient Risk Factors for High-Level Viremia
A comparison was performed between patient and graft
characteristics in those with either no viremia or a peak
viremia <10,000 copies/mL (n ¼ 74) versus 10,000 copies/
mL (n ¼ 51, Table 2). Because the deﬁnition of high-level
viremia remains controversial, a second analysis used
25,000 copies/mL (n ¼ 31) as the cut-off value for high-
level viremia [38]. In both analyses we found no associa-
tion between high-level viremia and recipient age, diagnosis,
conditioning regimen, or graft characteristics.Transplant Outcomes and the Association with Peak
HHV-6 Viremia
CBT outcomes for the entire patient cohort (N ¼ 125)
were analyzed with a median follow-up among survivors of
31.8 months (range, 4.4 to 77.2 months). Day 100 neutrophil
and platelet engraftment were 98% (95% CI, 94 to 100) and
80% (95% CI, 73 to 87), respectively. The median unit-to-
recipient HLA match of the engrafting unit was 6/10 alleles
(range, 2 to 9/10), and themedian infused total nucleated cell
count of the engrafting unit was 2.2  107/kg (range, 1.2 to
11.3). The incidence of day 100 grades II to IV acute GVHD
was 51% (95% CI, 42 to 60). Day 100 TRMwas 11% (95% CI, 5 to
17). One-year relapse incidence was 11% (95% CI, 6 to 17), and
the 1-year DFS was 65% (95% CI, 57 to 74).
Cox regression analysis tested the association between
level of viremia within the ﬁrst 100 days and CBT outcomes
(Table 3). Therewas no difference in the speed and success of
neutrophil and platelet engraftment, acute GVHD, or TRM by
100 days after CBT or in DFS 1-year post-transplant in pa-
tients with high-level (10,000 copies/mL) viremia versus
no or low-level (<10,000 copies/mL) viremia. Speciﬁcally,Level HHV-6 Viremia versus High-Level HHV-6 Viremia
iremia
L, n ¼ 74)
High-Level Viremia
(10,000 copies/mL, n ¼ 51)
P
43 (range, 1-64) .89
65 (range, 10-125) .13
.05
38 (48)
13 (28)
.26
34 (44)
8 (50)
9 (29)
5/6 (range, 4-6/6) .55
0) 6/10 (range, 3-9/10) .13
.3) 2.2 (range, 1.4-10.7) .08
.9 (range, .2-3.7) .57
CLL, chronic lymphocytic leukemia; TBI, total body irradiation; TNC, total
Table 3
Cox Regression Analysis of No or Low (<10,000 Copies/mL, n ¼ 74) versus High (10,000 Copies/mL, n ¼ 51) Peak Viremia Within the First 100 Days and
Transplant Outcomes (N ¼ 125)
Sustained Engraftment* at
100 Days
Day 100 Grades II-IV Acute GVHD Day 100 TRM 1-Year DFS
Neutrophils Platelets
HR for 10,000 viremia (95% CI) .98 (.68-1.41) 1.01 (.68-1.50) 1.41 (.86-2.31) 1.04 (.51-2.13) .71 (.39-1.30)
P .92 .95 .17 .90 .27
HR indicates hazard ratio.
* Estimate incorporates speed and success of neutrophil and platelet engraftment (speed and success).
Figure 2. Relationship between HHV-6 viral load and absolute lymphocyte
(ALC) recovery after CBT. There was a signiﬁcant association between absolute
lymphocyte recovery (measured in K/mL) and resolution of HHV-6 viremia. The
HHV-6 viral load in the ﬁrst 60 days post-CBT is shown in black circles and ALC
recovery is shown in red stars (all values for all patients). The solid lines are
splines over time for HHV-6 viremia (black) and ALC recovery (red),
respectively.
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engraftment was 22 days (range, 7 to 38) versus 21 days
(range, 7 to 43 days) in the high and no/low viremia groups,
respectively. Additionally, the median time to platelet
engraftment was 48 days (range, 32 to 99 days) versus
46 days (range, 21 to 90 days) in high and no/low viremia
groups, respectively. In a second analysis using a peak
viremia cut-off  25,000 copies/mL (n ¼ 31) within the ﬁrst
100 days, we also found no differences in engraftment, acute
GVHD, TRM, or DFS between groups (data not shown).
Relationship between HHV-6 and CMV Viremia
We compared rates of HHV-6 viremia according to
recipient CMV serostatus. There were no differences in the
rates of HHV-6 viremia in CMV-seropositive and CMV-
seronegative patients, with 28 of 70 CMV-seropositive
(40%) and 23 of 55 CMV-seronegative patients (42%)
developing high-level HHV-6 viremia. In addition, using
time-dependent Cox regression, the incidence of CMV reac-
tivation in CMV-seropositive patients was not different in
patients who developed high- versus low-level HHV-6
viremia (hazard ratio, 1.04; 95% CI, .60 to 1.80; P ¼ .897).
Relationship between HHV-6 Viremia and Absolute
Lymphocyte Recovery
To evaluate for a potential association between HHV-6
viremia and immune reconstitution, we analyzed viral load
over time and the recovery of absolute lymphocyte counts.
We found these were negatively correlated with a Spear-
man’s correlation coefﬁcient of r ¼ e.339 (P ¼ .009)
(Figure 2).
Treatment of HHV-6 Viremia
One hundred ten patients either reactivated HHV-6 and
never reactivated CMV or reactivated HHV-6 before CMV. In
this patient cohort, HHV-6 viremia kinetics were compared
in those patients whose HHV-6 was treated with foscarnet
(n ¼ 31) and those whose HHV-6 was observed (n ¼ 79,
Table 4). Patients treated for HHV-6 received foscarnet
promptly after viremia reactivation. Treated patients were
more likely to be febrile at HHV-6 onset: 22 of 31 observed
patients (71%) were febrile (median, 38.7C; range, 38 to
40.5) compared with 30 of 79 observed patients (38%) (me-
dian, 38.8C; range, 38 to 39.6; P < .01). Moreover, although
the onset of HHV-6 viremia and time to peak viremia were
similar between groups, treated patients had a signiﬁcantly
higher peak HHV-6 viremia (P< .01). Notably, the duration of
HHV-6 viremia (days to resolution) was similar in the 2
groups.
In CMV-seropositive patients who initially received fos-
carnet therapy for HHV-6, subsequent CMV reactivation was
delayed compared with those whose HHV-6 viremia was
observed: 59 days (range, 46 to 81) versus 39.5 days (range,19 to 274) after CBT (P ¼ .004). In addition, 2 patients whose
HHV-6 was observed (but no HHV-6 treated patient) later
developed CMV pneumonia. Finally, 7 additional patients of
the study cohort were not included in the above analysis of
the 110 patients because they reactivated CMV before HHV-6.
In these, foscarnet therapy for CMV abrogated subsequent
HHV-6 viremia (data not shown).
A day 45 landmark analysis was performed in patients
who reactivated HHV-6 by day 45 to evaluate the effect of
therapy on survival. The 1-year DFS survival of foscarnet-
treated patients (n ¼ 27) was 62% (95% CI, 41 to 78)
compared with 72% (95% CI, 61 to 81) in observed patients
(n ¼ 78) (log-rank test P ¼ .843).DISCUSSION
CB has been successfully used as an alternative HSC
source for the treatment of hematologic malignancies in
patients who do not have suitably HLA-matched adult do-
nors. Progression-free survival after single-unit CBT in chil-
dren [39] or double-unit CBT in adults [32,40,41] is
comparable with hematopoietic allografts from matched
unrelated adult donors. CBT carries a high risk of infectious
morbidity and mortality [42,43], however, and the incidence
and severity of HHV-6eassociated disease may be increased
in this population [13,15]. The naïve T cells in CB, and hence
the absence of HHV-6 primed T cells, may contribute to the
Table 4
Comparison of HHV-6 Viremia Kinetics in 110 Patients in Whom HHV-6
Viremia Was Either Observed or Treated with Foscarnet
HHV-6 Characteristics Observed Patients
(n ¼ 79)
Treated Patients
(n ¼ 31)
Onset, day 20 (10-40) 19 (10-56)
Peak, copies/mL 3800 (100-148,000) 24,100 (2000-160,000)
Day of peak 23 (12-42) 21 (14-57)
Foscarnet onset, day d 24 (17-83)
Foscarnet duration, day d 9 (1-22)
Viremia duration,* day 9 (1-49) 8 (1-60)
Values are medians, with ranges in parentheses.
* Reﬂects number of days from ﬁrst to last positive.
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ease attributable to HHV-6, including limbic encephalitis and
pneumonia, has been reported in CBT recipients when the
viral copy number exceeds 10,000 copies/mL [37,44].
Furthermore, Hill et al. [13] reported the incidence of HHV-
6eassociated post-transplant acute limbic encephalitis was
more frequent (9.9%) and associated with higher mortality
after CBT than adult donor HSCT.
In 125 CBT recipients from a single center, we found that
nearly all patients (94%) reactivated HHV-6 early after
transplantation, with 41% of patients reactivating to
levels  10,000 copies/mL. No patient or graft characteristic
correlated with high-level viremia. This viremia incidence is
higher than the 69% incidence in 54 CBT recipients reported
by Betts et al. [38], the 76% reactivation rate reported in 21
CBT recipients by Zerr et al. [45], and the 72% incidence in 68
CBT recipients reported by Hill et al. [13]. However, we
observed a lower median peak viremia of 7,600 copies/mL
than that reported by Hill et al. [13] (median peak viral load
in that study was 34,000 copies/mL with the upper limit of
the range> 1million). No patient in our analysis had viremia
> 1million copies/mL. Studies reporting high viral loads may
have included some patients with chromosomal integration
because 1 viral copy may exist per WBC (1  107 HHV-6
genomes/mL whole blood) [46]. A factor that may be even
more important in interpretation of HHV-6 studies is that
differences in incidences of viremia and viral loads may be
explained by varying sensitivities of different PCR assays as
has previously been described for both Epstein-Barr virus
and CMV infections [47,48]. The high incidence of viremia in
this study could potentially be explained by an overly sen-
sitive PCR at our institution. This considerably complicates
therapy guidelines because a widely applicable viremia
threshold for treatment cannot be currently recommended.
Although we observed a higher incidence of viremia than
prior reports [13,38,45], our series is notable for a very low
incidence of HHV-6 encephalitis (less than 2% as compared,
for example, with the 9.9% reported by Hill et al. [13]). In
addition, although subtle neurocognitive deﬁcits described
by others [16] may not have been detected in our retro-
spective analysis, no other types of end-organ disease were
diagnosed in our population, although 2 of 4 patients with
HHV-6 isolated from the BAL received foscarnet therapy for
viremia that potentially could have abrogated pulmonary
disease. The low number of encephalitis patients precluded
any evaluation of risk factors for end-organ disease, although
both patients with encephalitis had viral loads > 10,000
copies/mL. We cannot rule out that our intervention with
foscarnet therapy mitigated subsequent end-organ disease
in the 31 treated patients. Although the 79 patients who
were observed (Table 4) did not develop disease, theirmedian peak viremia levels were lower than treated patients.
This could have contributed to the relatively low level of
disease in our study. Only a large randomized controlled trial
would be able to further investigate this question.
There was no association between the development of
high-level viremia and CBT outcomes, including sustained
donor engraftment, acute GVHD, day 100 TRM, and DFS. DFS
was also comparable in a landmark analysis when foscarnet
therapy was taken into account. Although consistent with
the ﬁndings of Betts et al. [38] from the standpoint of sur-
vival, this is in contrast with Dulery et al. [29], who reported
that high-level viremia adversely affected overall survival,
and the ﬁndings of Zerr et al. [45], who reported HHV-6
reactivation was associated with higher rates of acute
GVHD and mortality in 315 allograft recipients (including 21
CBTs). It would also suggest that routine ex vivo generation
of cytotoxic T lymphocytes for HHV-6 for adoptive immu-
notherapy [49] may not be warranted.
Because the clinical implications of HHV-6 viremia are
unclear, clinical management has been inconsistent, espe-
cially given the substantial concerns regarding the toxicity of
foscarnet therapy [50-52]. Nevertheless, recognizing the
limitations of a retrospective review of nonrandomized pa-
tients, this varying clinical practice permitted the compari-
son of the natural history of viremia in patients who were
observed with those who were treated. Treated patients
were more likely to be febrile, had higher viral loads, and
promptly responded to therapy. As a group, patients who did
not receive foscarnet had lower levels of viremia and,
notably, had resolution of viremia without therapy. The
mechanism of viral clearance is of great interest given this is
observed in the ﬁrst 6 weeks after transplantation. We
postulate that the omission of antithymocyte globulin from
the pretransplant conditioning could have facilitated the low
incidence of encephalitis and the ability of many patients to
resolve without therapy. The signiﬁcant association between
diminishing viral load and lymphocyte recovery (Figure 2)
merits further investigation into the role of innate natural
killer cell immunity and T cell repertoire recovery in HHV-6
clearance.
It is evident from this study that it remains unclear which
patients require and/or beneﬁt from therapy for HHV-6
viremia after CBT. Moreover, even the need for routine viral
monitoring is open to question, as is the value of therapy in
asymptomatic patients. This is practically relevant because
many patients may be able to be safely observed. At this time,
however, we recommend HHV-6 monitoring in CBT re-
cipients because our understanding of HHV-6 is incomplete
and because this population as transplanted at MSKCC
remain at a low but ﬁnite risk of end-organ disease.
Furthermore, detection of viremia, especially at high levels,
will enhance clinician vigilance for early signs of end-organ
disease, such as subtle neurocognitive deﬁcits that could
otherwise be overlooked in patients with incipient enceph-
alitis, or other symptoms, such as pneumonitis, which has
been reported in other studies of allograft recipients.
At this time we strongly consider therapy in patients with
symptoms like fever or with very high levels of viremia
>25,000 copies/mL at MSKCC, although the risk-to-beneﬁt of
this approach in thosewithout evidence of end-organ disease
is not established and would require a large randomized
study. The CMV status of the patient can also be taken into
account in this decision-making given foscarnet treatment of
HHV-6 viremia delays subsequent CMV reactivation. This is at
least 1 practical beneﬁt ofHHV-6 therapy in CMV-seropositive
A.L. Olson et al. / Biol Blood Marrow Transplant 20 (2014) 787e793792CBT recipients given their high CMV reactivation rate and
attendant morbidity in CMV-seropositive CBT recipients [53].
Additionally, patients who are treated for HHV-6 viremia
without evidence of end-organ disease are given lower doses
of foscarnet (the equivalent of maintenance doses for CMV
viremia) to mitigate the nephrotoxicity of foscarnet therapy.
Ultimately, clinicians will require greatly enhanced knowl-
edge of HHV-6 biology to improve management of CBT pa-
tients who are at risk for both HHV-6 end-organ disease and
the toxicity of pre-emptive therapy. Standardization of PCR
assayswould also greatly assist in theunderstandingofHHV-6
biology in allograft recipients and ultimately aid in therapy
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